1Petrovich Z, Baert L, Bagshaw MA, et al. Adenocarcinoma of the prostate : innovations in management. Am J Clin Oncol. 1997,20 : 111.
2Robinson GR, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium -89. Nucl Med Biol. 1987,14:219.
3Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase - Ⅲ trial to evaluate the efficacy of strontium - 89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer, Int J Radiati Oncol Biol Phys. 1993,25:805.
4Robinson GR, Preston DF, Sxhiefelvein M, et al. Strontium- 89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995, 274:420.
5Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium - 89 and external beam radiotherapy in metastatic prostate cancer. Radiotherpay Oncol. 1994,31:33.
6Smith H, Navani A, Fishman SM. Radiopharmaceuticals for palliation of painful osseous metastases. Am J Hosp Palliat Med. 2004,21 (4) : 303.
7Robinson RG, Preston DF, Spicer JA, et al. Radionuclide therapy of intractable bone pain. Emphasis on strontium - 89. Semin Nucl Med. 1992,22:28.
8Pandit - Tasker N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004,45(8) :1358.
3MG Lam,de Klerk JM,van Rijk PP,BA Zonnenberg.Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases[].Anti-cancer agents in medicinal chemistry.2007
4Yong Li,Xiao-Feng Li,Yuanyuan Ma,Na Fang,James Russell,Duo Ma,Xiaorong Sun,Xia Han,Haishan Yang,Seigo Kinuya.Changes in the Levels of CD4<sup> </sup> and CD8<sup> </sup> T-Lymphocytes After Strontium-89 Chloride Therapy for Painful Bone Metastases in Patients Correlate with Treatment Efficacy[].Cancer Biotherapy & Radiopharmaceuticals.2007
5Ashok KR. Saxena,Sanjeev Kumar.Management Strategies for Pain in Breast Carcinoma Patients: Current Opinions and Future Perspectives[].Pain Practice.2007
6Hillegonds Darren J,Franklin Stephen,Shelton David K,Vijayakumar Srinivasan,Vijayakumar Vani.The management of painful bone metastases with an emphasis on radionuclide therapy[].Journal of the National Medical Association.2007
7Lam M G E H,Hoekstra A,de Klerk J M H,van Rijk P P,Zonnenberg B A.Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP[].Nuklearmedizin Nuclear medicine.2009
8Montesano T,Giacomobono S,Acqualagna G,Colandrea M,Di Nicola A,Travascio L,Giancamerla M,D’Apollo R,Toteda M,Ugolini F,Filesi M,Ronga G.Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study[].La Clinica terapeutica.2009
9Fang Na,Li Yong,Xu Yan-Song,Ma Duo,Fu Peng,Gao Hui-Qi,Gao Feng-Tong,Yang Hai-Shan,Yang Zhi-Jie.Serum concentrations of IL-2 and TNF-alpha in patients with painful bone metastases: correlation with responses to 89SrCl2 therapy[].Journal of nuclear medicine : official publication Society of Nuclear Medicine.2006
10Sciuto Rosa,Festa Anna,Rea Sandra,Pasqualoni Rosella,Bergomi Serenella,Petrilli Germana,Maini Carlo L.Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial[].Journal of nuclear medicine : official publication Society of Nuclear Medicine.2002
